BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 23, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Stalevo levodopa/carbidopa/entacapone regulatory update

FDA is reviewing the cardiovascular safety of Stalevo levodopa/carbidopa/entacapone from Orion after a meta-analysis of 15 trials showed an increased incidence of cardiovascular events in patients receiving the Parkinson's disease (PD) drug compared to patients receiving carbidopa/levodopa. The analysis, which included about 4,800 patients, showed there were significantly...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >